Loading
A phase 1 trial of [225Ac]Ac-ETN029 run by Novartis Pharmaceuticals, now recruiting.
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors is a phase 1 interventional study registered as NCT07006727 by Novartis Pharmaceuticals, with 116 participants planned, started 2025-10-16. Conditions recorded: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma and Medullary Thyroid Carcinoma. Interventions recorded: 225Ac-ETN029 and 111In-ETN029.
Shares Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer, Prostate cancer and the tag pipeline.
Shares Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Novartis, Prostate cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
Shares Extrapulmonary neuroendocrine carcinoma, Neuroendocrine tumours and the tag pipeline.
Shares Novartis, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/